Company
Theromics
Theromics is developing a next-generation thermal accelerant technology for enhanced ablation procedures and more precise and effective drug delivery.
Also known as Theromics Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- West Bridgewater, MA, United States
- Founded
- 2016
- Legal name
- Theromics Inc.
Record updated 28 September 2026
About
Theromics is leveraging next generation thermal accelerant technology to enhance soft tissue ablation procedures and more effectively deliver existing immunotherapy treatments. The company’s proprietary nanogels, HeatSYNC™ and CryoSYNC, are protein-based injectable nano-polymers that enhance the movement of energy in tissue, allowing more focused, precise ablations. Theromics was founded and spun out of Brown University in 2016 and is led by a team of accomplished clinicians, researchers and entrepreneurs committed to optimizing treatment strategies for a broad range of indications.
Funding snapshot
- Total raised
- $2.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $1.1M2023-04-28
Funding rounds
- Round, 2023
- $1.1M2023-04-28, SEC form D sold, 16 investors
- Round, 2020
- $1M2020-10-02, SEC form D sold, 17 investors
- Round, 2019
- $125K2019-08-09, SEC form D sold, 2 investors
- Round, 2018
- $100K2018-06-22, SEC form D sold, 1 investor
Products
- Other
- CryoSYNC
- Other
- HeatSYNC